Partnership launched with fully-contracted
#CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters
NEW
YORK, Dec. 19, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company"), a commercial-stage, cancer prevention medical
diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
today announced that it has entered into a strategic partnership
with VITALExam LLC (VITALExam), a comprehensive medical care
provider for first responders founded by Chief Executive Officer
Marci Vitale, DNP, FNP-BC,
AGACNP-BC, to enhance access to Lucid's EsoGuard®
Esophageal DNA Test for firefighters at risk for esophageal
precancer. Lucid and VITALExam launched the partnership with a
fully-contracted #CheckYourFoodTube Precancer Testing Event at
Tuscaloosa Fire Rescue in
Tuscaloosa, AL, as part of Lucid's
expanded direct contracting initiative focused on driving
near-term EsoGuard revenue.
"We commend Dr. Vitale and the VITALExam team on its
unwavering commitment to first responder health and are looking
forward to this partnership," said Shaun
O'Neil, Lucid's President and Chief Operating Officer.
"Their expertise and dedication to providing comprehensive care for
firefighters make them an invaluable ally in our mission to prevent
esophageal cancer deaths in at-risk patients. This collaboration
aligns us with a like-minded organization, strengthens our ability
to reach high-risk populations, and enables us to generate
contractually-guaranteed revenue through fully-contracted
#CheckYourFoodTube Precancer Testing Events. We look forward to
offering EsoGuard to fire departments in the communities VITALExam
serves."
"Integrating EsoGuard into our services perfectly complements
our mission to protect first responders' health," said Dr. Vitale.
"This partnership enables us to offer cutting-edge precancer
screening to the brave individuals who put their lives on the line
daily. At VITALExam, we're passionate about early detection and
empowering first responders to prioritize their health. By
introducing EsoGuard testing into our annual wellness program for
Tuscaloosa Fire Rescue, we are
making these exams more comprehensive and impactful, furthering our
shared mission of saving lives through early detection."
VITALExam is a comprehensive medical care provider dedicated to
optimizing the wellness of first responders. Founded by Dr. Vitale,
the company offers a range of services including cancer screenings,
comprehensive physicals, and behavioral health assessments,
utilizing advanced technology and evidence-based practices to
provide the highest level of care to those who serve our
communities.
Firefighters have a 62% increased risk of developing esophageal
cancer, and a 39% increased risk of dying from the same, according
to the Firefighter Cancer Support Group. To learn more about
hosting a #CheckYourFoodTube Precancer Testing Event, please
visit www.esoguard.com/request-an-event.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company,
and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on
the millions of patients with gastroesophageal reflux disease
(GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device, represent
the first and only commercially available tools designed with the
goal of preventing cancer and cancer deaths through widespread,
early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes
forward-looking statements that involve risk and uncertainties.
Forward-looking statements are any statements that are not
historical facts. Such forward-looking statements, which are based
upon the current beliefs and expectations of Lucid's management,
are subject to risks and uncertainties, which could cause actual
results to differ from the forward-looking statements. Risks and
uncertainties that may cause such differences include, among other
things, volatility in the price of Lucid's common stock; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required to
advance Lucid's products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from Lucid's clinical and preclinical studies; whether and
when Lucid's products are cleared by regulatory authorities; market
acceptance of Lucid's products once cleared and commercialized;
Lucid's ability to raise additional funding as needed; and other
competitive developments. In addition, Lucid continues to monitor
the COVID-19 pandemic and the pandemic's impact on Lucid's
businesses. These factors are difficult or impossible to predict
accurately and many of them are beyond Lucid's control. In
addition, new risks and uncertainties may arise from time to time
and are difficult to predict. For a further list and description of
these and other important risks and uncertainties that may affect
Lucid's future operations, see Part I, Item 1A, "Risk Factors," in
Lucid's most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, as the same may be updated in
Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form
10-Q filed by Lucid Diagnostics after its most recent Annual
Report. Lucid disclaims any intention or obligation to
publicly update or revise any forward-looking statement to reflect
any change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-partners-with-vitalexam-to-enhance-esophageal-precancer-detection-for-firefighters-302335948.html
SOURCE Lucid Diagnostics